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Abstract The presence of ionotropic glutamate receptor pro-
teins in islets of Langerhans and pancreatic /l-celllines (MIN6, 
HIT T1S, RINmSF) was investigated. For this purpose im-
munoblot analysis of /l-cell membranes was performed with sub-
unit-specific antibodies. We identified NMDARI subunits of the 
NMDA and KA-2 subunits of the kainate receptors, but did not 
detect GluRI subunits of the AMPA receptor. The receptor sub-
units present were shown to be glycosylated. /l-cell membranes 
contained specific binding sites for glutamate receptor ligands, 
and NMDA increased insulin secretion. These results demon-
strate that ionotropic glutamate receptor proteins, similar to 
those in the central nervous system, are expressed in rat pancre-
atic /l-cells. 
Key lI'ords: lonotropic glutamate receptor; Islets of 
Langerhans; RINm5F cells; MIN6 cells; HIT Tl5 cells; Insulin 
secretion 
1. Introduction 
Glutamate receptors are generally thought to be the principal 
neurotransmitter receptors responsible for excitatory neuro-
transmission in the central nervous system (CNS) [1,2]. The 
fast, excitatory postsynaptic responses of neurones to L-gluta-
mate are evoked by ligand-gated ionotropic receptors, of which 
there are three subtypes. These subtypes, which are classified 
on the basis of pharmacological and electro physiological re-
sponses to selective agonists and sequence homologies, are the 
AMPA (GluRI-4 or GluRA-D), the kainate (GluR5-7 and 
KA-l, KA-2) and the NMDA receptors (NMDARI and 
NMDAR2A-D). lonotropic glutamate receptors are hetero-
oligomenc protein complexes, composed of probably five sub-
units [3]. The receptor complexes are glutamategated non- se-
lective ion channels, permeable to monovalent cations but, de-
pending on their subunit composition, they exhibit differential 
permeabilities to divalent cations [3]. 
In addition to the important role that glutamate receptors 
play in the brain, recent evidence suggests a physiological role 
of glutamate in the endocrine pancreas. Neuronal ionotropic 
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glutamate receptor mRNAs have been found in a pancreatic 
,B-cellline, MIN6, [4] and in islets of Langerhans [5]. However, 
the presence of a receptor subunit mRNA in a cell may not 
necessarily indicate expression of the receptor protein [5,6]. It 
has for example. been reported that a pheochromocytoma cell 
line, PCI2, expresses NMDA receptor mRNA but not receptor 
protein [8]. Therefore, it is important to investigate whether or 
not the ionotropic glutamate receptor mRNA found in ,B-cells 
is actually translated into protein. In the present study we used 
subunit-specific antibodies and ligand binding assays to deter-
mine that rat islets of Langerhans and ,B-celllines express ion-
otropic glutamate receptor subunit proteins similar to those 
found in the CNS. The effect of glutamate and selective syn-
thetic agonists on insulin secretion from islets of Langerhans 
and ,B-ce1l lines was also investigated. 
2. Materials and methods 
2 1. Production and pUrlfication of antibodies 
Synthetic peptJdes corresponding to reSidues 436-450 ofNMDARI 
(CTGPNDTSPGSPRHT [9]) and reSidues 950-965 of KA-2 
(RPRPGPTGPRELTEHE [10]) were prepared usmg solid-phase syn-
thesis. The NMDAR 1 143• 45U) peptJde was coupled to mercaptosuccinyl-
ated ovalbumm carrier protein [II] via the N-termmal cysteine of the 
peptide which was conjugated to S-thio-2-111tro benzoic acid (TNB) 
prior to coupling. The KA-2m0-96s) peptide was conjugated to ovalbu-
min with glutaraldehyde [12]. The ovalbumin-coupled peptide antigens 
were co-adsorbed With an adjuvant peptide to collOidal gold particles 
(100 nm) [13]. Antibodies were raised by immulllzmg two New Zealand 
white female rabbits (4 to 6-month-old) With each antigen. Serum anti-
body titers were mOllitored ten days after the second and subsequent 
injectIOns by ELISA using the appropnate peptide bound to the mi-
crotitration plates. The anti-NMDAR{436-45() antibodies were immu-
noaffillity punfied using the synthetic peptide (5 mg) coupled to acti-
vated thiopropyl Sepharose 4B (Pharmacia). Antibodies directed 
against the KA-2Iysu_96S) peptide were purified using BSA-coupled pep-
tides immobilized on Affi-GellS (BIO-Rad). Other steps of the purifica-
tIOn procedure were performed as previously described [12]. 
2::. Memhrane preparatIOn from ,B-cells, islets of Langerhans and brain 
Culture of ,B-celilines (MIN6, HIT TIS, RINm5F), membrane prep-
aration from cultured cells, and the Isolation of rat islets of Langerhans 
were performed as described previously [14] Membranes from whole 
brams or dissected cortical, hippocampal, cerebellar and spmal cord 
areas of adult Wlstar rats (250-300 g) were prepared as described earlier 
[12,15]. Before radIO ligand binding assays, all membrane fractions were 
washed a further three times by resuspension and centnfugation in 50 
mM Tris-cltrate (pH 7.4) at 4°C for 20 min at 54,000 x g. 
2 3. Degiycosylation oj memhrane protems 
Membrane samples were resuspended m 50 mM sodium phosphate 
buffer (pH 7.0) to a final concentratIOn of 10 mg protein/m!. The 
membranes were denatured by boiling in 1% SDS for 10 mm, and then 
octyl-,B-o-glycopyranoside (Sigma) was added to a final concentration 
of 2% octyl-,B-o-glycopyranoside, 0.1 % SDS and 1 mg protein/ml in 50 
mM sodium phosphate buffer (pH 70). The preparatIOn was then 
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incubated at 3rC with or without N-glycosidase F (6 uillts/ml, 
Boehnnger Mannhelm GMBH, Germany) for 4 h. Reactions were 
terminated by boiling in SDS-PAGE sample buffer. 
2 4 Sodium dodeeyl sulphate-polyacrylamide gel electrophoresis, 
electrophoretic transfer of protems and imlllunobiot analysis 
SDS-PAGE was performed on 10% gels [16]. Proteins were trans-
ferred electrophoretically onto poly(vmyhdene difluonde) microporous 
membrane (Immobilon; Millipore Co. Bedford, MA. USA) using a 
Multlphor II NovaBiot Electrophoretic Transfer Uillt with a disconti-
nous buffer system for 2 h at room temperature as recommanded by 
the manufacturer (LKB Produkter AB, Bromma, Sweden). Before im-
munostaming, the Immobilon sheets were blocked overnight at 4°C 
with 5% non-fat dry mIlk and 1.50 dIlution of normal swme serum m 
PBS (blocking solution). The protems on ImmobIion sheets were re-
acted wIth different affinity-purified antibodies (2-5 .ug/ml) in blockmg 
solutIOn for 12-16 h at 4°C. The bound antibodies were detected with 
an alkahne phosphatase-conjugated anti-rabbit IgG secondary anti-
body [12]. 
2.5 RadlOligand binding 
Radioligand binding studies were carned out by a centrifugation 
assay, using polyethylene glycol 6000 (PEG) precIpitation. Membrane 
protein samples (0.2 mg) were incubated in 50 mM Tris-citrate (pH 7.4) 
for 30 min at 2°C. using either 20 nM [3H]AMPA in the presence of 
100 mM KSCN or 10 nM eH]KA. Non-specific binding was deter-
mined usmg lOO.uM AMPA or KA, respectIvely. Followmg incuba-
tion, 2 mg/ml human y-globulins and 15% (w/v) PEG were added and 
the samples centrifuged at 10,000 x g m an Eppendorf microfuge for 
2 mm. The supernatant was aspirated and the pellet nnsed tWIce super-
fiCIally using 0.4 ml ice-cold 15% PEG. The pellets were suspended in 
0.5 ml of 1% SDS and then transferred to scintillatIOn vIals and counted 
after the addItion of 4 ml Liquiscint (National DIagnostIcs, ManvIlle, 
NJ, USA). 
2.6 Measurement of msulin release 
Freshly isolated Islets were preincubated for I h at 37°C m HEPES/ 
Krebs buffer (119 mM NaCI. 4.75 mM KCI, 5 mM NaHC03, 2.5 mM 
CaCI2, 1.2 mM KH2PO., 20 mM HEPES-Na, pH 74) con taming 3.3 
mM glucose and 2 mg/ml BSA [17]. Samples were then incubated for 
an addItional 2 h m 0.6 ml HEPES/Krebs buffer containing 3.3 mM, 
8.3 mM or 16.7 mM glucose m the presence or absence of vanous 
glutamate receptor agonists (0.5 and 2.5 mM glutamate, 0.5 mM ka-
inate. 0.5 mM NMDA with 0.01 mM glycme) Insuhn release was 
measured by radioimmunoassay as described by Ashcroft and Crossley 
[18], except that separatIOn of free and bound msulin was achieved 
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FIg. I. Characterization of the specifiCIty of anti-KA-2(951!-96SI polyclonal 
antibody using transfected cells, and dIstribution of KA-2 subunits in 
rat CNS. Aliquots (50.ug of proteinllane) of membrane proteins from 
COS-7 cells expressing the indicated glutamate receptor subunits fol-
lowing cDNA transfection (GluR5-7 and KA-2; 0, nontransfected con-
trol) and membrane fractIOns from vanous regions of the rat CNS 
(CTX, cerebral cortex; HIP, hippocampus; CER, cerebellum; SPc. 
spinal cord) were subjected to SDS-PAGE and immunoblotted wIth 
antibodies generated against C-terminal residues 950-965 of the KA-2 
glutamate receptor subunit. The pOSItIOns of the molecular weight 
markers are mdlcated on the left. 
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Table I 
SpeCIfic [lH]AMPA and eH]KA bindmg activity of membranes pre-
pared from rat brain, MIN6 and RINm5F ,B-cell lines 
Membrane [3H]AMPA binding [3H]KA binding activity 
sample activity 
-------------------
(fmol/mg) (% of brain) (fmol/mg) (% of brain) 
Rat brain 381.8 ± 32.4 100 196.1 ± 12.7 100 
MIN6 80.6 ± 5.9 21.1 ± 1.6 13.0 ± 0.6 6.6 ± 0.3 
RINm5F 21.6 ± l.l 5.7 ± 0.3 7.7 ± 0.7 4.0 ± 0.4 
Specific [lH]AMPA and CH]KA binding actiVIties were determmed by 
centrifugatIOn assay using PEG precIpitation. The bindmg assays were 
performed in triplicate, and the values are the mean ± S.D. from the 
three mdependent determinatIOns. 
usmg anti-gumea-pig sohd phase second antibody (Sac-Cel, IDS Ltd., 
Boldon, UK). 
3. Results 
3.1. Characterization and specificity of the antibodies 
To study the expression pattern of different ionotropic gluta-
mate receptor subunit proteins, antipeptide antibodies were 
raised against the N-terminal domain of NMDARI (residues 
436-450 [9]), the C-terminal region of KA-2 (residues 950-965 
[10]) and N- and C-terminal epitopes of GluRI (residues 253-
267 and 877-889 [19]). The production, purification and char-
acterization of anti-GluR I (253-::'67) and anti-GluRl(877-889) rabbit 
polyclonal antibodies have been described previously 
[12,20.21]. 
The specificity of the anti-KA-2(95(1--965) rabbit polyclonal anti-
body was tested on immunoblots of cDNA-transfected COS-7 
cells expressing various kainate-preferring glutamate receptor 
subunits (Fig. I). This antibody detected a 120 kDa protein 
only in those cells which were transfected with eDNA coding 
for the KA-2 protein. According to amino acid sequences re-
ported by Herb et al. [10], the antigenic domain of the KA-2 
subunit used here has no homology with the corresponding 
region in KA-l, which was confirmed previously with an anti-
body raised against residues 954-965 of KA-2 [22]; therefore 
the 120 kDa band represents only the KA-2 glutamate receptor 
subunit. A similar protein was labelled in membrane samples 
isolated from rat brain. The immunostaining with the anti-
KA-2(950-965) antibody was stronger in samples prepared from 
cerebral cortex or hippocampus than with membranes from 
cerebellum or spinal cord (Fig. 1). The reactivity of the anti-
body with the native glutamate receptor protein was also tested 
by immunoprecipitation of the [3H]kainate binding activity. 
Immunoprecipitation studies were carried out on rat brain (cer-
ebral cortex) membranes solubilized in Triton X-IOO under 
conditions which give soluble binding sites for both AMPA and 
kainate [12,23]. Solubilized preparations were incubated with 
the antibody coupled to protein A-Sepharose and antibody 
binding was determmed by measuring the reduction in [,H]ka-
inate or [3H]AMPA binding relative to controls [12]. Using 
different anti-KA-2(95o_9651 immune sera; 42 ± 11 % (rabbit R15) 
and 39 ± 8% (rabbit R16) of the total [3H]kainate binding activ-
ity was immunoprecipitated while no eH]AMPA binding activ-
ity was removed. 
Antibody to NMDARI was raised against a unique region 
of the receptor (residues 436-450) which does not have corre-
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Fig. 2. Immunodetection of ionotroplc glutamate receptor subumts III bralll, pancreatic ,B-cells and islets of Langerhans ExpreSSIOn of NMDAR L 
(A); KA-2, (8) and GluRI (e) subunits was tested by subumt-specific antlpeptide antibodies. Membrane fractions were prepared from rat cerebral 
cortex (eTX), rat islets of Langerhans (Ill and pancreatic ,B-ceillines. Membrane proteins (50 flg of protein or 100 Islets/lane) were fractIOnated 
by SDS-PAGE, transferred to an Immobilon filter and probed with subunit-specific purified anti-NMDARl ,430--150) (A), anti-KA-219511_oo51 (8), 
antJ-GluRl,253_267) and antJ-GluRl,87J_RR91 (el antibodies as described III section 2. The positions of the molecular weight markers are Illdlcated on 
the left. 
sponding regions in other non-NMDA ionotropic receptor pro-
teins [24] and does not show sequence homology with the 
corresponding regions of other NMDA receptor subunits. To 
confirm the subunit specificity of the anti-NMDARl I436-450) an-
tibody, the corresponding regions of other NMDAR2 receptor 
subunits (residues 439--453 of NMDAR2A. residues 436--449 
of NMDAR2B, residues 450--464 of NMDAR2C and residues 
465--477 of NMDAR2D [25,26] were synthesized. Using a 
dot blot assay with these synthetic peptides, the anti-
NMDAR I 1436-450) antibody reacted only with the peptide de-
rived from the NMDARI protein (not shown). On im-
munoblots, the anti-NMDARI
'436-4501 polyclonal antipeptide 
antibody recognized a single band representing a protein with 
an apparent molecular weight of 115 kDa in membrane samples 
prepared from rat bram (Fig. 2A, CTX) or transfected COS-7 
cells expressing the NMDARla receptor subumt (not shown). 
Preimmune sera showed no Immunoreacticity. For the im-
munoblot analysIs, immunoaffinity purified antibodies were 
used routinely. The preincubation of these antipeptide antibod-
ies with the respective synthetic peptide (20 j1g peptide/ml) 
resulted in the disappearance of specific labelling. 
3.2. Immlllwchenllcal identification of d{f/erent ionotropic 
glutamate receptor subunits in pancreatic fJ-cells and in islets 
of Langerhans 
Antibodies against the putative extracellular domain of the 
rat NMDAR 1 glutamate receptor subunit detected a band of 
115 kDa in membrane proteins prepared from rat brain, and 
showed a similar but weaker labelling of proteins in islets of 
Langerhans and fJ-celllines (Fig. 2A). The molecular weight of 
these proteins closely approximates that expected for the 
NMDARI subunit on the basis of amino acid sequence 
(103,477 Da [9]) taking into account subunit glycosylation. By 
Immunoblot analysis, the anti-KA-2 antibody detected a pro-
tein of 120 kDa which corresponds to the molecular weight of 
the glycosylated KA-2 subunit in rat brain membranes [22]. A 
lower amount of this subunit was also identified in islets of 
Langerhans and fJ-celllines (Fig. 2B). Both antipeptide polyclo-
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nal antibodies, which recognize different N- and C-terminal 
peptide sequences of the lOS kDa GluRl protein [12,20,21], 
yielded the same staining pattern in membranes prepared from 
rat cerebral cortex (Fig. 2C). In contrast. neither anti-GluRI 
antibody detected this receptor subunit in membranes prepared 
from fJ-celllines (Fig. 2C). 
Because the molecular weights of the immunochemically 
identified NMDAR I and KA-2 receptor subunits were some-
what higher than those calculated from the amino acid se-
quences, we used a glycosidase enzyme, which specifically re-
moves N-linked sugars, to determine the non-glycosylated mo-
lecular weight of these proteins. Enzymatic deglycosylation of 
NMDARI and KA-2 with PNGase F resulted in a lower molec-
ular weight (103 kDa and 109 kDa, respectively) for these 
proteins both in cerebral cortex and in fJ-cell membranes (Fig. 
3) consistent with the fact that both NMDARI and KA-2 have 
several consensus sites for N-linked glycosylation [9,10]. 
3.3. Determination of ligand hlllding actzvity oj glutamate 
receptors in pancreatic fJ-cells 
The presence of glutamate receptors fJ-cell was detected by 
[,H]AMPA (in the presence of 100 mM KSCN) and [3H]kainate 
binding in membrane samples prepared from rat brain and 
MIN6 or RINmSF fJ-cell lines (Table I). Compared to the 
neuronal membrane fraction, much lower [,H]AMPA and 
[3H]kainate specific ligand binding activity was detected in pan-
creatic fJ-cell lines. These data are consistent with our im-
munoblotting studies in suggesting a lower amount of active 
receptor proteins in pancreatic fJ-cells compared to neuronal 
membranes. 
3.4. The effect of ionotropic glutamate receptor agonists 011 
lllsulill secretion 
The rate of insulin secretion from rat islets of Langerhans at 
3.3 mM glucose (3.0 ± 0.4 ,uU/h per islet) was not affected by 
O.S mM glutamate, NMDA or kainate. At 8.3 mM glucose, the 
rate of insulin secretion was increased by 0.5 mM NMDA (in 
the presence of the NMDA-receptor co-agonist glycine) from 
65 ± 4 to 96 ± 8 ,uU/h per islet. Neither glutamate nor kainate 
(O.S mM) had a significant effect. At 16.7 mM glucose O.S mM 
NMDA increased secretion from 130 ± 14 to 179 ± 20 ,u U/h 
per islet; O.S mM kainate elicited a smaller rise which did not 
achieve statistical significance; no effect of O.S mM glutamate 
was found. Even at 2.S mM glutamate did not enhance insulin 
secretion at any of the glucose concentratIOns tested. 
4. Discussion 
4.1. 101l0tropzc glutamate receptor subunit proteins are 
expressed in pancreatic fJ-cells and in islets of Langerhans 
Immunodetection with subunit-specific antibodies indicated 
the presence of NMDAR1 and KA-2 proteins in islets of 
Langerhans and the pancreatic fJ-celllines MIN6, HIT TIS and 
RINmSF. The antibody reaction with the denatured receptor 
proteins in immunoblots and [3H]AMPA and [3H]kainate li-
gand binding assays of membranes suggest a significantly lower 
amount of receptor proteins in the islet and fJ-cell samples 
compared to membranes prepared from rat brain. 
A limited population of the glutamate receptor subunit 
mRNAs was found m the mouse clonalfJ-cellline MIN6 using 
RT-PCR [4]. Detected subunits were GluR3. KA-2, NMDAI. 
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FIg. 3. EnzymatIc deglycosylatIOn of ionotropic glutamate receptor 
subunits In braIn and pancreatic ,B-cells. Membranes (50 flg) from 
rat cerebral cortex (CTX). MIN6 (MIN). RINm5F (RIN) and HIT Tl5 
(HIT) ,B-cell lines were Incubated with (+PNGase F) or wIthout 
(- PNGase F) glycosldases. subjected to SDS-PAGE and Immunoblot-
ted with antI-NMDARl(.3h-450) or antI-KA-2(950 965) antibodies as indi-
cated on the figure. The figure Illustrates that NMDARI and KA-2 
receptor subumts have approximately 10-12 kDa lower molecular 
weIght after deglycosylatIOn. 
NMDAR2D; very low expression levels of GluR2 and 
NMDAR2C were also found. In the rat clonal fJ-cell line 
RINmSF, the same probes amplified a somewhat different 
combination of subunit mRNAs; GluR2, KA-l, KA-2, 
NMDAR I. NMDAR2D, and a very low signal for GluRS [S]. 
In pancreatic islets the following receptor subunit mRNAs were 
found: GluR2. GluR3. GluR6, GluR7. KA-2, NMDAR1, 
NMDAR2D, and trace amounts of GluR1, NMDAR2A and 
NMDAR2C [S]. The two fJ-celllines expressed different combi-
nations of receptor subunit mRNAs probably because of the 
different species origin. However, RINSmF, which originates 
from rat, also contained different mRNAs compared to rat 
islets of Langerhans. The different expression pattern of the 
receptor subtypes in this case can be explained by the presence 
of other cell types in pancreatic islets or by a change in the 
subunit pattern expressed on transformation of fJ-cells. There-
fore from these PCR results it is difficult to conclude which 
subunits are present in the native pancreatic fJ-cells. Our data 
using subunit-specific immunoprobes indicate that GluRl pro-
tein is not detectable in any of the fJ-celllines studied whereas 
KA-2 and NMDARI subunit proteins are expressed in all 
studied fJ-celllines and also in islets of Langerhans. This con-
firms the finding that mRNAs for KA-2 and NMDAR I were 
present in MIN6. RINmSF and islet cells, and is consistent with 
the observation that GluR I mRNA was not detected in fJ-cell 
lines [4,S]. 
Although some subunits can form functional homomeric re-
ceptors when expressed in oocytes or cultured cells, current 
evidence indicates that most functional receptor complexes 
found in brain are made up of more than one distinct subunit. 
Four related subunits (GluRI-4) make up the AMPA receptor 
hetero-oligomer complex. Electrophysiological experiments 
show that neither KA-I nor KA-2 subunits form a functional 
receptor when expressed alone but do so when co-expressed 
with GluRS or GluR6 [10,27]. suggesting that functional ion 
channels in the central nervous system are made up of com-
binations of GluRS-7, KA-I and KA-2. Expression of 
E. Molnar l't al / FEBS Letters 371 (1995) 253-257 
NMDAR2A-D ar0ne does not lead to formation of functional 
channels )n Xenopus oocytes [25,28]. Formation of NMDA-
operated channels. however, is greatly enhanced when anyone 
of these NMDAR2 subunits is co-expressed with NMDARI. 
Together these findings indicate that the NMDARI subunit 
may be es,ential for the formation of functional NMDA-oper-
ated channels in the CNS. Because one or more subunits in 
addition to NMDARI and KA-2 are probably necessary for 
expression of functional channels in mammalian cells, further 
studies with subunit protein specific probes are required to 
define the subunit composition of the functional j3-cell gluta-
mate receptor(s). 
4.2. Effect of ionotropic glutamate receptor agonists on insulin 
secretion 
We found that NMDA enhanced glucose-induced insulin 
secretion; however, under our experimental conditions the re-
sponse was small and. moreover. glutamate. which is the en-
dogenous ligand of the receptor. had no effect even at relatively 
high concentration (2.5 mM). In earlier studies. kainate. 
AMPA and NMDA in the presence of 3.3 mM glucose stimu-
lated insulin secretion from MIN6 cells [4]. Both kainate and 
AMPA (but not NMDA) in the presence of 8.3 mM glucose 
moderately (1.2-1.8 fold) stimulated insulin secretion from rat 
islets of Langerhans [5]. In both of these two studies. the effect 
of glutamate was not reported. however. Bertrand et al. [29] 
reported a transient stimulation of insulin secretion by gluta-
mate in perfused pancreas. This short transient insulin response 
to glutamate is probably blunted during the long-lasting static 
incubation applied for conventional insulin secretion measure-
ments. which may reflect rapid desensitisation of these recep-
tors [1]. The study of[CA2+1 with the fluorescent Ca2+ indicator 
dye fura-2 and whole cell patch-clamp recording indicated the 
presence of functional NMDA, kaillate and AMPA gated ion 
channels in j3-cells. however. the frequency of glutamate recep-
tor agonist-responsive j3-cells was relatively low [4.5]. 
Our results clearly indicate that some of the ionotropic gluta-
mate receptor subunit proteins are present in islets of Langer-
hans and in j3-celllines and may playa role in insulin secretion. 
However. the expression of varying receptor mRNAs in differ-
ent j3-celllines. the rather modest effects of glutamate receptor 
ligands on insulin secretion. and the low incidence of gluta-
mate-responsive j3-cells suggest that caution should be exer-
cised in ascribing major functional significance to these recep-
tors III the regulation of insulin secretion. Further studies are 
needed to characterise and quantitate the various other ion-
otropic glutamate receptor subunits and their splice variants in 
j3-cells in detail. The investigation of functional ionotropic glu-
tamate receptors containing limited combinations of subunits 
1llj3-cell would be also a potentially useful expenmental system. 
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